Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs, a leader in the field of gene-engineered T cells for cancer therapy, offers gene packaging and delivery services for the generation of TCR-modified T cells. Relying on our advanced technologies and rich experience, we can provide the most professional TCR transfection for the most cutting-edge genetically modified immunotherapies.
T lymphocytes play a crucial role in immunity and there are various gene therapy strategies targeting T cells. The efficient gene transfer into T cells facilitates the treatment of several genetic dysfunctions, inherited diseases and acquired diseases. TCR gene transfer via cell fusion or electroporation is also shown to confer MHC restricted specificity to nonspecific T cells. However, these initial processes are generally inefficient for a great number of T cells for clinical application.
Retroviral: the advent of retroviral vectors not only makes gene transfer more efficient at large scale but also enables the stable integration of exogenous genes. Despite demonstrations of scalability and stable expression, retroviral vectors require full T-cell activation for efficient gene transduction that may, in certain culture systems, inhibit cell function.
Lentiviral: lentiviral vectors have the potential to be safer from the perspective of insertional mutagenesis and they have substantially higher transduction efficiency for genetically engineering human T cells. Recently, lentiviral vectors have emerged as a favorable vector system for stably expressing two-gene TCRs, which require dual gene expression. Bicistronic lentiviral vectors that provide for high-level tumor or viral antigen-specific TCR gene expression in T cells have been developed to show strong promise for clinical application.
Electroporation: electroporation-mediated mRNA transfection is an alternative and promising approach without many limitations associated with gene transfer vectors that insert in the genome. mRNA manufacture and delivery does not require the significant costs of manufacture and testing that exogenous viral vectors need.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
